Imaging Biometrics Ltd
IBAI · Main Market · Health Care · mcap £2.5m · 0.9p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 01 Oct 26 | Strengthening pipeline prominent US institutions
Q3 2026 Shareholder Update: strengthening pipeline of prominent US institutions |
+11.1% | |
| 15 Sep 26 | Adoption of Advanced Brain Tumor Imaging Platform
("Imaging Biometrics", the "Company" or, together with its subsidiaries, the "Group") |
+22.0% | |
| 28 Aug 26 | US Academic Medical Centre Adopts IB Clinic
("Imaging Biometrics", the "Company" or, together with its subsidiaries, the "Group") |
+5.0% | |
| 29 Jul 26 | Results | Half-year Results
Imaging Biometrics Limited (the "Company" or the "Group") |
+0.0% |
| 14 Jul 26 | Sub-division
Further to the announcements of 12 May and 3 June, the Company is pleased to confirm that the sub-division has completed with a resulting 246,709,789 ordinary shares of £0.005. |
+0.0% | |
| 09 Jun 26 | Publication of Phase 1 Clinical Trial
Publication of Phase 1 Clinical Trial of Oral Gallium Maltolate (GaM) in Recurrent Glioblastoma and Reopening of Expanded Access Programme |
−3.1% | |
| 05 Jun 26 | Results | Commercialisation, Phase II Results & Revenue Path
IB Neuro™ Commercialisation Plan - ASCO 2026 Phase II Results and Strategic Revenue Pathway |
+16.7% |
| 03 Jun 26 | AGM Statement and Business Update
Imaging Biometrics Limited (LSE: IBAI) is pleased to provide this update to shareholders ahead of its Annual General Meeting being held today. |
+0.0% | |
| 13 May 26 | Amendement To Notice Of Annual General Meeting
The Company notes an error to RNS 12 May 2026 (RNS Number: 0280E), that incorrectly stated that the ordinary shares of £0.01 will be sub-divided into one ordinary share of £0.0005. |
+0.0% | |
| 08 May 26 | KIRKSTALL AWARDED BBSRC/NC3Rs GRANT: GLIOBLASTOMA
KIRKSTALL AWARDED BBSRC/NC3Rs GRANT FOR GLIOBLASTOMA 'TUMOUR ON A CHIP' RESEARCH |
+0.0% | |
| 30 Apr 26 | Results | Annual Report for the Year Ended 31 December 2025
Publication of Annual Report for the Year Ended 31 December 2025 |
+0.0% |
| 19 Feb 26 | Board change | Board Appointment
Imaging Biometrics Limited (LSE: IBAI) is pleased to announce the appointment of John Charles Richardson as a Non-Executive Director with effect from 1 March 2026 and will become a member of the remuneration and audit co |
−8.2% |
| 11 Feb 26 | Update and IB Nimble Webinar – 27 February 2026
Imaging Biometrics Limited ('IBAI') comprises two subsidiary businesses, Imaging Biometrics LLC and Kirkstall Limited. |
+5.3% | |
| 16 Jan 26 | Strategic Direction Fueling Organic Growth
Imaging Biometrics, Ltd, (LSE: IBAI) is pleased to provide an update on its involvement in the development of gallium maltolate as well as its strategic priorities for 2026. |
−35.3% | |
| 10 Dec 25 | Expansion Global Distribution Agreement with GE
Imaging Biometrics Expands Global Distribution Agreement with GE HealthCare to Include FTB Express Maps and QSMetric™ |
+11.1% | |
| 26 Nov 25 | Release of Next-Generation IB Clinic
Imaging Biometrics Announces Release of Next-Generation IB Clinic |
+8.1% | |
| 24 Nov 25 | Board change | Directorate Change
The Company announces that Dr Al Musella will step down from the Board of Directors with effect from 31 December 2025. |
+0.0% |
| 13 Nov 25 | Fractional Tumor Burden Mapping Enhances GBM Trial
Imaging Biometrics' Fractional Tumor Burden Mapping Enhances GBM Trial |
+11.1% | |
| 10 Nov 25 | IB Announces Completion of Phase 1 Trial of GaM
Imaging Biometrics Announces Successful Completion of Phase 1 Trial of Gallium Maltolate in Recurrent Glioblastoma |
+60.0% | |
| 16 Oct 25 | Further Re: Purchase of interest in Kirkstall Ltd
Further Re: Purchase of interest in Kirkstall Limited |
+0.0% | |
| 14 Oct 25 | Purchase of Kirkstall and CLN - Correction
Purchase of Kirkstall Limited and CLN with Truetide plc - Correction |
−16.7% | |
| 14 Oct 25 | Purchase of Kirkstall and CLN with Truetide plc
Purchase of Kirkstall Limited and CLN with Truetide plc |
−16.7% |
Company filings. Not investment advice.